A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson

References

• WHO. Global coronavirus statistics. United Nations. Published 2021 [Accessed 2021 Mar 30]. https://covid19.who.int/region/amro/country/us
   Google Scholar
• Hapshy V, Aziz D, Kahar P, Khanna D, Johnson KE, Parmar MS. COVID-19 and pregnancy: risk, symptoms, diagnosis, and treatment. SN Compr Clin Med. 2021;1–12. doi:10.1007/s42399-021-00915-2.
   PubMedGoogle Scholar
• Suri JS, Agarwal S, Gupta SK, Puvvula A, Biswas M, Saba L, Bit A, Tandel GS, Agarwal M, Patrick A, et al. A narrative review on characterization of acute respiratory distress syndrome in COVID-19-infected lungs using artificial intelligence. Comput Biol Med. 2021;130:104210. doi:10.1016/j.compbiomed.2021.104210.
   PubMed Web of Science ®Google Scholar
• CDC. Symptoms of coronavirus. Centers for Disease Control. Published 2021. Updated 2021 [Accessed 2021 Mar 29]. https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html
   Google Scholar
• WHO. Timeline: WHO’s COVID-19 response. World Health Organization. Published 2021 [Accessed 2021 Mar 30]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/interactive-timeline
   Google Scholar
• Calina D . Towards effective COVID19 vaccines: updates, perspectives and challenges (Review). Int J Mol Med. 2020;46(1):3–16. doi:10.3892/ijmm.2020.4596.
   PubMed Web of Science ®Google Scholar
• FDA. FDA approves first COVID-19 vaccine. FDA. Published 2021 Updated 2021 Aug 23. [Accessed 2021 Sept 20]. https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine
   Google Scholar
• Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Raabe V, Bailey R, Swanson KA. Publisher correction: phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2021;590(7844):E26–E26. doi:10.1038/s41586-020-03098-3.
   PubMed Web of Science ®Google Scholar
• Biontech PA . Pfizer And Biontech Conclude Phase 3 Study Of Covid-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints; 2020. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine
   Google Scholar
• FDA. Pfizer-BioNTech COVID-19 vaccine EUA Amendment Review Memorandum. fda.gov. USA: Food and Drug Administration; 2021 April 9.
   Google Scholar
• Moderna. Emergency use authorization (EUA): moderna COVID-19 Vaccine. Moderna. Published 2021 [Accessed 2021 Mar 16]. https://www.modernatx.com/covid19vaccine-eua/
   Google Scholar
• Jackson LA, Anderson EJ, Rouphael NG. An mRNA Vaccine against SARS-CoV-2 - preliminary report. New Eng J Med. 2020;383:11.
   Web of Science ®Google Scholar
• Pardi NH, Hogan MJ, Naradikian MS. Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J Exp Med. 2018;6:17.
   Google Scholar
• Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C. Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New Eng J Med. 2020;383(27):2603–15. doi:10.1056/NEJMoa2034577.
   PubMed Web of Science ®Google Scholar
• Biontech Pfizer 31 Mar. Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents; 2021. United States: Pfizer. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-biontech-announce-positive-topline-results-pivotal
   Google Scholar
• Tian F. Mutation N501Y in RBD of Spike Protein Strengthens the Interaction between COVID-19 and its Receptor ACE2. Elife 2021;10. doi:10.7554/eLife.69091
   Web of Science ®Google Scholar
• Xie X. Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera. Res Sq [Preprint]. 2021. doi:10.21203/rs.3.rs-143532/v1.
   Google Scholar
• Haas E, Angulo F, McLaughlin J, Anis E, Singer S, Khan F, Brooks N, Smaja M, Mircus G, Pan K. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819–29. doi:10.1016/S0140-6736(21)00947-8.
   PubMed Web of Science ®Google Scholar
• Rosen B, Waitzberg R, Israeli A. Israel’s rapid rollout of vaccinations for COVID-19. Isr J Health Policy Res. 2021;10(1):6. doi:10.1186/s13584-021-00440-6.
   PubMed Web of Science ®Google Scholar
• Bar-On YM . Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. N Engl J Med. 385(15): 1393–1400. doi:10.1056/NEJMoa21142552021
   PubMed Web of Science ®Google Scholar
• Mofaz M, Yechezkel M, and Guan G. [Preprint] 15 Sep 2021 . Self-reported and physiological reactions to the third BNT162b2 mRNA COVID-19 (booster) vaccine dose. medRxiv doi:10.1101/2021.09.15.21263633.
   Google Scholar
• World Health Organization. COVID-19 weekly epidemiological update. World Health Organization. Published 2021. Updated 2021 May 9. [Accessed 2021 May 14]. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19—11-may-2021
   Google Scholar
• Tang P, Hasan MR, Chemaitelly H et al. 2021 . BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B.1.617.2) variant in Qatar. Nat Med. 27(12): 2136–2143. doi:10.1038/s41591-021-01583-4.
   PubMed Web of Science ®Google Scholar
• Bernal JL, Andrews N, Gower C et al. 2021 . Effectiveness of COVID-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 385(7): 585–594. doi:10.1038/s41591-021-01583-4 .
   PubMed Web of Science ®Google Scholar
• Tartof SY, Slezak JM, Fischer H, et al. [Preprint] . Six-Month effectiveness of BNT162B2 mRNA COVID-19 Vaccine in a large US integrated health system: a retrospective cohort study. SSRN; 2021. doi:10.2139/ssrrn.3909743.
   Google Scholar
• Garvey LH, Nasser S. Anaphylaxis to the first COVID-19 vaccine: is polyethylene glycol (PEG) the culprit? Br J Anaesth. 2021;126(3):e106–e108. doi:10.1016/j.bja.2020.12.020.
   PubMed Web of Science ®Google Scholar
• FDA. Pfizer-BioNTech COVID-19 vaccine. 2021.
   Google Scholar
• Wan E, Chui C, Lai F, et al . Bell’s palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study. Lancet Infect Dis. 2022;22(1): 64–7. doi:10.1016/S1473-3099(21)00451-5.
   PubMed Web of Science ®Google Scholar
• Moderna. Moderna’s work on our Covid-19 vaccine. Moderna. Published 2021. Updated 2021 Mar 5. [Accessed 2021 Mar 16. https://www.modernatx.com/modernas-work
   Google Scholar
• Fessenden J. Inside the new mRNA vaccines for COVID-19. UMass Medical School. 2020 Dec 18. https://www.umassmed.edu/news/news-archives/2020/12/inside-the-new-mrna-vaccines-for-covid-19/
   Google Scholar
• Baden LS, Essink HM. B. efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New Eng J Med. 2021;384(5):13. doi:10.1056/NEJMoa2035389.
   Web of Science ®Google Scholar
• Wu KK, Werner AP, Koch M, Choi A, Narayanan E, Stewart-Jones GBE, Colpitts T, Bennett H, Boyoglu-Barnum S, Shi W. M. serum neutralizing activity elicited by mRNA-1273 vaccine - preliminary report. New Eng J Med. 2021;384(15):1468–70. doi:10.1056/NEJMc2102179.
   PubMed Web of Science ®Google Scholar
• Edara VV, et al. [Preprint]. Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. bioRxiv. 2021. doi:10.1101/2021.05.09.443299
   Google Scholar
• Puranik A, Lenehan PJ, Silvert E, et al. Preprint . Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence. medRxiv. 2021 Oct 18. doi:10.1101/2021.08.06.21261707.
   Google Scholar
• CDC. Moderna COVID-19 vaccine information. CDC. Published 2021. Updated February 22, 2021. [Accessed 2021 Mar 16]. https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/index.html
   Google Scholar
• Johnson J. The Janssen COVID-19 Vaccine. Johnson & Johnson. Published 2021. [Accessed 2021 Mar 8]. https://www.janssencovid19vaccine.com/hcp.html
   Google Scholar
• Vaccines J, Randomized A. Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older. Johnson & Johnson. Published 2020. Updated 2020 Dec 14. [Accessed 2021 Mar 8]. https://www.jnj.com/coronavirus/ensemble-1-study-protocol
   Google Scholar
• Levine H. The 5 Stages of COVID-19 Vaccine Development: what You Need to Know About How a Clinical Trial Works. Johnson & Johnson. Published 2020 Sept 23. [Accessed 2021 Mar 10]. https://www.jnj.com/innovation/the-5-stages-of-covid-19-vaccine-development-what-you-need-to-know-about-how-a-clinical-trial-works
   Google Scholar
• Steinhauser G. South Africa Rolls Out J&J Covid-19 Vaccine to Healthcare Workers. The Wall Street Journal. Published 2021 [Accessed 2021 Mar 8]. https://www.wsj.com/articles/south-africa-rolls-out-j-j-covid-19-vaccine-to-healthcare-workers-11613564630
   Google Scholar
• Staff R. Bahrain first to approve Johnson & Johnson COVID-19 vaccine for emergency use - regulator. Reuters. Published 2021 [Accessed 2021 Mar 9]. https://www.reuters.com/article/health-coronavirus-bahrain-idUSS8N2I4021
   Google Scholar
• Pharmaceuticals J. Vaccine Technology. Janssen Global Services. Published 2021 [Accessed 2021 Mar 12]. https://www.janssen.com/infectious-diseases-and-vaccines/vaccine-technology
   Google Scholar
• Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, Stoop J, Tete S, Van Damme W, Leroux-Roels I, et al. Interim results of a phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine. New Eng J Med. 2021;384(19):1824–35. doi:10.1056/NEJMoa2034201.
   PubMed Web of Science ®Google Scholar
• Control CfD. Johnson & Johnson’s Janssen. Center for Disease Control. Published Updated 2021 Mar 4 [Accessed 2021 Mar 9]. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/janssen.html
   Google Scholar
• Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C, Fennema H, Spiessens B, et al. Safety and efficacy of single-dose Ad26.COV2.S Vaccine against Covid-19. New Eng J Med. 2021;384(23):2187–201. doi:10.1056/NEJMoa2101544.
   PubMed Web of Science ®Google Scholar
• Walker M. J&J COVID-19 vax effective against severe disease - but overall efficacy falls well short of competitors. MedPage. Published 2021 [Accessed 2021 Mar 11]. https://www.medpagetoday.com/infectiousdisease/covid19/90942
   Google Scholar
• Schwartz F. J&J Vaccine Highly Effective Against Delta Variant in South African Trial. The Wall Street Journal. Published 2021. Updated 2021 Aug 6 [Accessed 2021 Sept 20]. https://www.wsj.com/articles/j-j-vaccine-highly-effective-against-delta-variant-in-south-african-trial-11628292645
   Google Scholar
• Jongeneelen M, Kaszas K, Veldman D, et al. [Preprint] . Ad26.COV2.S elicited neutralizing activity against Delta and other SARS-CoV-2 variants of concern. bioRxiv. 2021. https://doi.org/10.1101/2021.07.01.450707.
   Google Scholar
• Oliver SE, Gargano JW, Scobie H, et al . The advisory committee on immunization practices’ interim recommendation for use of Janssen COVID-19 Vaccine - United States, February 2021. MMWR Morb Mortal Wkly Rep. 2021;70(9):329–332. doi:10.15585/mmwr.mm7009e4.
   PubMed Web of Science ®Google Scholar
• Mahase E. Covid-19: Johnson and Johnson vaccine trial is paused because of unexplained illness in participant. BMJ. 2020;371:m3967. doi:10.1136/bmj.m3967.
   PubMed Web of Science ®Google Scholar
• Rosenblum H, Hadler S, Moulia DE, Shimabukuro TT, Su JR, Tepper NK, Ess KC, Woo EJ, Mba-Jonas A, Alimchandani M. Use of COVID-19 vaccines after reports of adverse events among adult recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna): update from the advisory committee on immunization practices — United States, July 2021. MMWR Morb Mortal Wkly Rep. 2021;70(32):1094–99. doi:10.15585/mmwr.mm7032e4.
   PubMed Web of Science ®Google Scholar
• Fact sheet for healthcare providers administering vaccine [press release]. Johnson & Johnson. 2021 Feb 27.
   Google Scholar
• FDA. FDA and CDC lift recommended pause on Johnson & Johnson (Janssen) COVID-19 vaccine use following thorough safety review. U.S. Department of Health and Human Services. Published 2021. Updated April 23, 2021 [Accessed 2021 May 10]. https://www.fda.gov/news-events/press-announcements/fda-and-cdc-lift-recommended-pause-johnson-johnson-janssen-covid-19-vaccine-use-following-thorough
   Google Scholar